News

Cibus Announces Carlo Broos as New Interim CFO amid Change

Cibus Announces Carlo Broos as New Interim CFO amid Change

Cibus Announces Carlo Broos as Interim CFO

Cibus, Inc. has made a significant leadership change by appointing Cornelis (Carlo) Broos as the company's Interim Chief Financial Officer, effective immediately. Broos takes over the CFO role after the departure of Wade King, marking an important transition period for the company.

Carlo Broos: A Wealth of Experience

Carlo Broos, 53, is no stranger to Cibus. Since joining the company in 2011, he has played a critical role as Senior Vice President of Finance. His extensive background in finance, accounting, and audit makes him a strong fit for this interim position. Before coming on board with Cibus, Broos held several key leadership roles at Syngenta, including Head of Finance for the Europe, Africa, and Middle East regions and CFO for Syngenta in the Netherlands and Belgium.

Broos's robust educational background includes a Master of Science in Business Administration from Radboud University and a post-master's in accountancy from Tilburg University in the Netherlands. Additionally, he is a Registered Accountant in the Netherlands, which is akin to a Certified Public Accountant (CPA) in the U.S.

Corporate Transition and Financial Considerations

According to the information released, there are no material interests or transactions involving Mr. Broos that warrant disclosure. Furthermore, no new compensatory agreements will be established for his interim role. Meanwhile, Wade King will remain at Cibus in a non-executive position during this transition.

This leadership update comes after Cibus's recent 8-K filing with the Securities and Exchange Commission, signifying the company's ongoing commitment to transparency and effective governance. Cibus, Inc., previously known as Calyxt, trades under the stock ticker NASDAQ:CBUS.

Recent Developments in Cibus

In other notable news, Cibus recently executed a public offering of 3,000,000 shares, with Roth Capital Partners and A.G.P./Alliance Global Partners partially exercising an additional purchase option for 289,953 shares. This strategic move aimed at bolstering the company's capital position comes in light of current market conditions.

Moreover, Canaccord Genuity has adjusted its price target for Cibus's shares to $20, reflecting a decrease from the previous target of $21 while maintaining a Buy rating. Such shifts in price projections underline the ongoing challenges and adjustments the company is grappling with in response to market dynamics.

Market Position and Financial Analysis

Cibus, Inc. (NASDAQ:CBUS) finds itself at a critical crossroads as it navigates this leadership transition. Recent data unveils that the market capitalization of Cibus stands at approximately $93.75 million, showcasing its role in the agricultural chemicals sector. Despite impressive revenue growth of 816.72% in the past year, Cibus is encountering notable financial hurdles. The company's operating income margin is starkly negative at -2503.38%, pointing to considerable operational costs that outpace its revenue.

InvestingPro insights highlight that the company is rapidly depleting its cash reserves, raising concerns about profitability based on its recent financial history. This reality may have influenced the decision to appoint an experienced financial leader like Carlo Broos to steer the company through these challenges.

Stock Performance Trends

Recent stock performance has raised eyebrows, with a decline of 51.85% over the past month and an alarming drop of 82.11% in the past year. Such trends indicate that the stock is approaching its 52-week low, reflecting investor sentiments and market conditions. For those considering their investment strategies, these trends emphasize the importance of detailed research and consultation with financial advisors.

Frequently Asked Questions

Who is Carlo Broos?

Carlo Broos is the newly appointed Interim Chief Financial Officer of Cibus, bringing extensive financial expertise and experience in leadership roles from his tenure at Syngenta.

What does Carlo Broos's appointment mean for Cibus?

His appointment signifies a strategic move to stabilize the company’s financial position and navigate current challenges following the previous CFO's departure.

Has Cibus made any recent public offerings?

Yes, Cibus announced a public offering of 3,000,000 shares as part of efforts to strengthen its capital base.

What is Cibus's current market capitalization?

Cibus currently has a market capitalization of approximately $93.75 million.

How has Cibus's stock performed recently?

The stock has seen a significant decline, plummeting by 82.11% over the past year, leading investors to remain cautious.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 215

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 81

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 176

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Confirms Positive Outlook for Nucor with $240 Target

Updated Category News Views 58

Nucor Corporation, a key player in the steel industry, had its Buy rating reaffirmed by Citi, setting a price target of $240. This was no idle gesture; it came hand-in-hand with a revised earnings per share (EPS) estimate dropped to $1.38 from an earlier forecast of $1.76, aligning closely with Nucor’s own guidance that projected an EPS between $1.30 and $1.40 for the...

Continue Reading
Investment Insights: Stanley Druckenmiller's Regional Bank Strategy

Updated Category News Views 288

Understanding Stanley Druckenmiller's Investment Approach Billionaire investor and former hedge fund manager Stanley Druckenmiller is well known for his unique approach to investing. With a knack for macroeconomic analysis, he consistently predicts market movements by taking a top-down view. A Bold Move into Regional Banks Recently, Druckenmiller made headlines with his...

Continue Reading
FFW Corporation Declares Latest Quarterly Dividend Payment

Updated Category News Views 192

FFW Corporation Announces Quarterly Cash Dividend WABASH, Ind. — FFW Corporation (OTC PINK: FFWC), the parent company of Crossroads Bank, has recently announced a quarterly cash dividend of $0.31 per share for its common stock. This dividend will be payable soon, specifically on September 26, and it targets shareholders who are recorded as of September 12. Financial...

Continue Reading
Alaris Equity Partners Secures Final Prospectus for New Offering

Updated Category News Views 101

Alaris Equity Partners Completes Final Prospectus Filing CALGARY, Alberta — Alaris Equity Partners Income Trust, known as Alaris, has made a significant move in its financial strategy by filing a final short form prospectus in various provinces across Canada. This filing aligns with their previously announced offering to secure $100 million in 6.25% convertible...

Continue Reading
Xtreme Fighting Championships Exciting Return to South America

Updated Category News Views 133

Xtreme Fighting Championships Exciting Return to South America Recently, Xtreme Fighting Championships (XFC), backed by Xtreme One Entertainment, Inc. (OTC: XONI), confirmed its much-anticipated return to the vibrant landscape of South America. This marks a significant milestone for the organization, which previously hosted numerous thrilling events in the region....

Continue Reading